{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02568878",
            "orgStudyIdInfo": {
                "id": "01"
            },
            "organization": {
                "fullName": "Montana State University",
                "class": "OTHER"
            },
            "briefTitle": "Creatine for Depressed Male and Female Methamphetamine Users",
            "officialTitle": "An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "creatine-for-depressed-male-and-female-methamphetamine-users"
        },
        "statusModule": {
            "statusVerifiedDate": "2015-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2015-11"
            },
            "primaryCompletionDateStruct": {
                "date": "2016-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2017-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2015-10-01",
            "studyFirstSubmitQcDate": "2015-10-02",
            "studyFirstPostDateStruct": {
                "date": "2015-10-06",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2015-12-10",
            "lastUpdatePostDateStruct": {
                "date": "2015-12-11",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Tracy Hellem",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "Montana State University"
            },
            "leadSponsor": {
                "name": "Montana State University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users\n* Assess creatine's effect on methamphetamine use\n* Assess the safety of creatine in male methamphetamine users with depression"
        },
        "conditionsModule": {
            "conditions": [
                "Depression",
                "Anxiety",
                "Methamphetamine Dependence"
            ],
            "keywords": [
                "Depression",
                "Anxiety",
                "Methamphetamine dependence"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 29,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Creatine monohydrate",
                    "type": "EXPERIMENTAL",
                    "description": "5 grams of daily creatine monohydrate by mouth for 8 weeks",
                    "interventionNames": [
                        "Drug: Creatine monohydrate"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Creatine monohydrate",
                    "armGroupLabels": [
                        "Creatine monohydrate"
                    ],
                    "otherNames": [
                        "Creapure"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Hamilton Depression Rating Scale (HAMD) Scores",
                    "timeFrame": "This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation)."
                },
                {
                    "measure": "Hamilton Anxiety Rating Scale (HAMA) Scores",
                    "timeFrame": "This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation)."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Self-reported methamphetamine use",
                    "timeFrame": "This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation)."
                },
                {
                    "measure": "Incidence of treatment-emergent adverse events",
                    "timeFrame": "Adverse events will be reviewed monthly for safety concerns and presented at study completed (anticipated: 12 months after study initiation)."
                },
                {
                    "measure": "Percent of positive urine drug screens for methamphetamine",
                    "timeFrame": "This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation)."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse\n* Current diagnosis of major depressive disorder (primary or substance-induced)\n* Current diagnosis of an anxiety disorder (primary or substance-induced)\n* Current Hamilton Depression Rating scale score \\> or = to 16\n* Current Hamilton Anxiety Scale score \\> = to 18\n* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \\> = to 4 weeks prior to creatine treatment initiation\n\nExclusion Criteria:\n\n* Persons unable to provide adequate informed consent\n* Persons who are at clinically significant suicidal or homicidal risk\n* Primary substance-related diagnosis other than methamphetamine dependence or abuse\n* Positive pregnancy test (females only)\n* History of renal disease\n* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing\n* History of hypersensitivity reaction to creatine",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "59 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tracy Hellem, PhD",
                    "role": "CONTACT",
                    "phone": "406 243 2110",
                    "email": "tracy.hellem1@montana.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Tracy Hellem, PhD",
                    "affiliation": "Montana State University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Montana State University College of Nursing (Missoula campus)",
                    "status": "RECRUITING",
                    "city": "Missoula",
                    "state": "Montana",
                    "zip": "59812",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tracy Hellem, PhD",
                            "role": "CONTACT",
                            "phone": "406-243-2110",
                            "email": "tracy.Hellem1@montana.edu"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "4062432110"
                        },
                        {
                            "name": "Tracy Hellem, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.87215,
                        "lon": -113.994
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "submissionTracking": {
                "estimatedResultsFirstSubmitDate": "2024-02-12",
                "submissionInfos": [
                    {
                        "releaseDate": "2024-02-12",
                        "resetDate": "2024-03-11",
                        "mcpReleaseN": 2
                    },
                    {
                        "releaseDate": "2024-03-12",
                        "resetDate": "2024-04-08",
                        "mcpReleaseN": 3
                    }
                ]
            }
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003863",
                    "term": "Depression"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "relevance": "LOW"
                },
                {
                    "id": "M4324",
                    "name": "Anxiety Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11674",
                    "name": "Methamphetamine",
                    "relevance": "LOW"
                },
                {
                    "id": "T385",
                    "name": "Creatine",
                    "asFound": "Cardiovascular Risk",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Ot",
                    "name": "Other Dietary Supplements"
                }
            ]
        }
    },
    "hasResults": false
}